Last reviewed · How we verify
LD PepGNP-Dengue — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
LD PepGNP-Dengue (LD PepGNP-Dengue) — Gylden Pharma Ltd.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| LD PepGNP-Dengue TARGET | LD PepGNP-Dengue | Gylden Pharma Ltd | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- LD PepGNP-Dengue CI watch — RSS
- LD PepGNP-Dengue CI watch — Atom
- LD PepGNP-Dengue CI watch — JSON
- LD PepGNP-Dengue alone — RSS
Cite this brief
Drug Landscape (2026). LD PepGNP-Dengue — Competitive Intelligence Brief. https://druglandscape.com/ci/ld-pepgnp-dengue. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab